RPRoger R. Perry

Roger R. Perry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roger R. Perry has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Calcitonin-Secreting Pancreatic Neuroendocrine Tumor in a Patient with Multiple Endocrine Neoplasia Type 1

    by Umer A. Ansari, Christine L. Ramirez, Eric C. Feliberti, Aaron I. Vinik, Roger R. Perry


  • Cutaneous melanoma in Asian‐Americans

    by Susanna Shin, Bryan E. Palis, Jerri Linn Phillips, Andrew K. Stewart, Roger R. Perry

    Background: There is little information available on melanoma in non‐white populations. Our objective was to characterize melanoma in Asian‐Americans (AsA) and compare patient demographics and tumor characteristics with the non‐Hispanic White (NHW) population.Methods: 483,050 cutaneous melanoma patients diagnosed between 1986 and 2005 were identified using the National Cancer Data Base (NCDB); 1,237 were AsA, and 409,564 were NHW. Age, gender, site, histologic type, tumor thickness, AJCC stage, and survival were compared.Results: AsA were more likely to be diagnosed with acral lentiginous tumors (6.7%) than NHW (0.8%, P < 0.001). A greater proportion of AsA were diagnosed with T4 tumors (15.6%) than NHW (8.5%, P < 0.001). AsA presented with fewer early stage I–II tumors and more late stage III–IV tumors than NHW (P < 0.001). Survival was similar for AsA and NHW.Conclusions: This is the largest study to date on melanoma in AsA. Compared to NHW, AsA are more likely to have acral lentinginous tumors, thick tumors, and higher stage. Despite this, their survival is similar to the NHW population. J. Surg. Oncol. 2009;99: 114–118.


  • ENDOCRINE TUMORS OF THE GASTROINTESTINAL TRACT

    by Roger R. Perry, Aaron I. Vinik

    ▪ Abstract Endocrine tumors of the gastrointestinal tract produce a variety of secretory products that cause unique clinical syndromes. Diagnosis, which is often delayed, requires a strong index of suspicion and must be confirmed by biochemical tests. Precisely where these tumors originate remains a topic of controversy. However, several growth factors that may be involved in tumor development have been identified, and genetic abnormalities in patients with multiple endocrine neoplasia have been described. New pre- and intraoperative localization techniques have greatly increased the ability to identify and resect these tumors. The long-acting somatostatin analogue octreotide is frequently useful as a tracer to localize tumors and as symptomatic therapy for limiting release of secretory products produced by the tumors. In some instances it may also have direct anti-tumor activity.